Université de Liège


Centre Hospitalier Universitaire Sart-Tilman

Domaine Universitaire du Sart Tilman

4000 Liège






Project Leader

Prof. Dr. Frédéric Baron

Principal Investigator

Phone: +32 4 366 72 01

Fax:+32 4 366 88 55


Project Team

Professor, MD, PhD Yves Beguin

Head of department, supervision of the project; physician partly in charge of patients included in the clinical study
+32 4 366 72 01
+32 4 366 88 55


MD, PhD Evelyne Willems

Physician partly in charge of patients included in the clinical study



Grégory Ehx

PhD Student
Flow cytometry experiments for the project
+32 4 366 45 80
+32 4 366 88 55


Coline Daulne

Technician working on the project
+32 4 366 45 80
+32 4 366 88 55


Muriel Hannon, PhD

Flow cytometry experiments for the project
+32 4 366 45 80
+32 4 366 88 55




About the Centre Hospitalier Universitaire Sart-Tilman

The University of Liège is responsible for conducting the clinical study on CliniMACS-selected plus rapamycin-induced in vivo expanded Treg in cGVHD (study eudract # 2012-000301-71)

1) Hematology Group

The Hematology Group is a member of the GIGA-I3 (Infection, Immunity & Inflammation) group, itself part of the GIGA (Groupe Interdisciplinaire de Génoprotéomique Appliquée, www.giga.ulg.ac.be) research center of the University of Liège (CHU S-T). It has developed several major research avenues. In particular, active research programs are carried out on mesenchymal stem cells (MSC) for immunosuppression, as well as on the ability of regulatory T cells (Tregs) to attenuate graft-versus-host disease (GVHD). We have extensive expertise in pre-clinical studies involving cell transplantation in mice (i.e. humanized murine models of GVHD or of liver damage in NOD/SCID/IL-2Rγ(null) mice) and requiring analyses by flow cytometry. The laboratory has also a large experience in monitoring immune reconstitution after allogeneic hematopoietic cell transplantation. The work of the lab is highly facilitated by its access to the different GIGA technological platforms.

2) Laboratory of Cell and Gene Therapy

The Laboratory of Cell and Gene Therapy (LTCG) was built to GMP conditions in 2002 in the "Centre Hospitalier Universitaire" (CHU S-T) of Liège. The LTCG is a 220 m2 GMP-compatible facility for the collection, processing (including cell selection, expansion cultures), testing, storage and delivery of various cell types, including HSC, MSC, Tregs, lymphocytes and dendritic cells. The lab also incorporates a R&D unit for the development of new cell products for clinical use. It includes 3 FAHMP-approved tissue banks, a HSC bank, a non-hematopoietic cell bank, and a FACT-accredited cord blood bank containing more than 3,500 validated CB units available for worldwide distribution. Stem cell research and expertise in clinical scale manipulation of cell products have allowed the transfer of cell therapy applications to the clinical field. In particular, clinical protocols using Tregs or cultured MSC are ongoing in the CHU S-T of Liège to study their immunosuppressive effects after HSC transplantation.

3) Division of Hematology

The Division of Clinical Hematology at the CHU S-T of Liège is in charge of the diagnosis and treatment of hematological disorders. The division of Hematology strives to provide high-quality clinical care to patients, but also pursues a strong program of clinical research, partnering with pharmaceutical companies, universities and academic networks (such as the EORTC, IFM, Lysa, EBMT) to offer patients opportunities for participation in the best clinical trials. The Division of Hematology has developed the ULICE program for autologous and allogeneic HSC transplantation with family or unrelated marrow, peripheral blood or cord blood for malignant, genetic and other hematological disorders. The program is the second in size in Belgium (±100 transplants/year) and has received the international JACIE accreditation. In this setting, we carry out an important program of translational and clinical research, also performing many clinical trials. Among the academic clinical trials, several are multicenter studies sponsored by the CHU of Liège.

The TREGeneration partners


Newsletter Subscription

Please fill in the information of your subscription.


You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

TREGeneration celebrates WMDD Read more

Social Media

LinkedIn TREGeneration